[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334951-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334951-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","off-the-shelf-car-nk-cells-targeting-immunogenic-cell-death-marker-erp57-execute-robust-antitumor-activity-and-have-a-synergistic-effect-with-icd-inducer-oxaliplatin","Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin","","Chimeric antigen receptor natural killer (CAR-NK) therapy shows strong potential for hematologic malignancies, yet its performance against solid tumors is constrained by insufficient target availability and limited infiltration of engineered NK cells. This study evaluates whether ERp57, an immunogenic cell death (ICD) marker that can translocate from the endoplasmic reticulum to the cell surface after drug treatment, can serve as a CAR-NK therapeutic target.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/off-the-shelf-car-nk-cells-targeting-immunogenic-cell-death-marker-erp57-execute-robust-antitumor-activity-and-have-a-synergistic-effect-with-icd-inducer-oxaliplatin/334951/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/off-the-shelf-car-nk-cells-targeting-immunogenic-cell-death-marker-erp57-execute-robust-antitumor-activity-and-have-a-synergistic-effect-with-icd-inducer-oxaliplatin/334951.png","ImageObject",300,407,{"name":42,"@type":43},"Maeve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-25","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is ERp57 considered a potential target for CAR-NK therapy?","Question",{"text":63,"@type":64},"ERp57 is an immunogenic cell death (ICD) marker that can translocate from the endoplasmic reticulum to the cell surface after treatment. The study assesses ERp57 as a surface antigen that CAR-NK cells can recognize.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were ERp57-targeting nanobodies used to build CAR-NK cells?",{"text":68,"@type":64},"A VHH phage display library was screened to identify ERp57-targeted nanobodies. A high-affinity candidate nanobody against both human and mouse ERp57 was used for constructing CAR-NK cells.",{"name":70,"@type":61,"acceptedAnswer":71},"What role does oxaliplatin play in the observed antitumor effects?",{"text":72,"@type":64},"Low-dose oxaliplatin was shown to induce ERp57 translocation and enhance the antitumor activity of the resulting CAR-NK cells. The study reports a synergistic effect between CAR-NK cells and oxaliplatin.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334951,1790472998,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","Open access Original research  \n Off-the-shelf CAR-NK cells targeting  \nimmunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin  \nLiuhai Zheng,1,2 Huifang Wang,1,2 Jihao Zhou,1,3 Guangwei Shi,1,4 Jingbo Ma,1 Yuke Jiang,1 Zhiyu Dong,1 Jiexuan Li,1 Yuan-Qiao He,5,6 Dinglan Wu,7 Jichao Sun,1 Chengchao Xu,1,8,9 Zhijie Li  ,1 Jigang Wang1,8,10,11,12  \nTo cite: Zheng L, Wang H, Zhou J, et al. Off-the-shelf CARNK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin. Journal for ImmunoTherapy of Cancer 2024;12:e008888 . doi:10.1136/jitc-2024-008888  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2024-008888](jitc-2024-008888)) .  \nLZ, HW and JZ contributed equally.  \nAccepted 13 June 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nJigang Wang;  \n[jgwang@icmm.ac.cn](jgwang@icmm.ac.cn)  \nProfessor Jichao Sun;  \n[sunjichao@mail.sustech.edu.cn](sunjichao@mail.sustech.edu.cn)  \nChengchao Xu; [ccxu@icmm.ac.cn](ccxu@icmm.ac.cn)  \nDr Zhijie Li;  \n[li.zhijie@szhospital.com](li.zhijie@szhospital.com)  \nABSTRACT  \nBackground Chimeric antigen receptor natural killer (CAR-NK) therapy holds great promise for treating hematologic tumors, but its efficacy in solid tumors is limited owing to the lack of suitable targets and poor infiltration of engineered NK cells. Here, we explore whether immunogenic cell death (ICD) marker ERp57 translocated from endoplasmic reticulum to cell surface after drug treatment could be used as a target for CAR-NK therapy.  \nMethods To target ERp57, a VHH phage display library was used for screening ERp57-targeted nanobodies (Nbs) . A candidate Nb with high binding affinity to both human and mouse ERp57 was used for constructing CAR-NK cells. Various in vitro and in vivo studies were performed to assess the antitumor efficacy of the constructed CAR-NK cells.  \nResults We demonstrate that the translocation of ERp57 can not only be induced by low-dose oxaliplatin (OXP) treatment but also is spontaneously expressed on the surface of various types of tumor cell lines. Our results show that G6-CAR-NK92 cells can effectively  \nkill various tumor cell lines in vitro on which ERp57 is induced or intrinsically expressed, and also exhibit potent antitumor effects in cancer cell-derived xenograft and patient-derived xenograft mouse models. Additionally, the antitumor activity of G6-CAR-NK92 cells is synergistically enhanced by the low-dose ICD-inducible drug OXP. Conclusion Collectively, our findings suggest that ERp57 can be leveraged as a new tumor antigen for CAR-NK targeting, and the resultant CAR-NK cells have the potential to be applied as a broad-spectrum immune cell therapy for various cancers by combining with ICD inducer drugs.  \nINTRODUCTION  \nImmunotherapy strategies such as immune checkpoint blockades and adoptive immune cell transfer (ACT) that aim to fight cancers by enhancing the functions of patients’ immune systems or leveraging the killing capability  \n\n| WHAT IS ALREADY KNOWN ON THIS TOPIC |\n| --- |\n| ⇒ During immunogenic cell death, a key hallmark is the translocation of some endoplasmic reticulum proteins to the cell surface. Whether these proteins translocated to the cell surface can be used as therapeutic targets has not been investigated, so it is significant to explore the possibility of these proteins as chimeric antigen receptor natural killer (CAR-NK) targets.\u003Cbr>WHAT THIS STUDY ADDS |\n| ⇒ We found that ERp57 is spontaneously expressed on the surface of various types of tumor cell lines, and low-dose oxaliplatin treatment can also ind","cbCair2oDPGWKbrq","https://ap.wps.com/l/cbCair2oDPGWKbrq","pdf",10906411,17,"English","# Abstract\n# Introduction\n## Background on CAR-NK and target limitations\n## Rationale for ERp57 as an ICD marker target\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy","[{\"question\":\"Why is ERp57 considered a potential target for CAR-NK therapy?\",\"answer\":\"ERp57 is an immunogenic cell death (ICD) marker that can translocate from the endoplasmic reticulum to the cell surface after treatment. The study assesses ERp57 as a surface antigen that CAR-NK cells can recognize.\"},{\"question\":\"How were ERp57-targeting nanobodies used to build CAR-NK cells?\",\"answer\":\"A VHH phage display library was screened to identify ERp57-targeted nanobodies. A high-affinity candidate nanobody against both human and mouse ERp57 was used for constructing CAR-NK cells.\"},{\"question\":\"What role does oxaliplatin play in the observed antitumor effects?\",\"answer\":\"Low-dose oxaliplatin was shown to induce ERp57 translocation and enhance the antitumor activity of the resulting CAR-NK cells. The study reports a synergistic effect between CAR-NK cells and oxaliplatin.\"}]","Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin | PDF",1790008973,43]